Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

310
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
310
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

296
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
296
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

588
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
588

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems.

Diabetes technology & therapeutics·2026
Same author

Prevalence, incidence, mortality, and years of life lost to diabetes from 1996 to 2024 in Denmark.

BMJ open diabetes research & care·2026
Same author

A Diabetes Management Protocol with Subcutaneous Insulin During Induced Labor and Delivery in Women with Type 1 or Type 2 Diabetes.

Diabetes technology & therapeutics·2026
Same author

Outcomes Following Infusion of Insulin Into Ultrasound-Detected Hyperechogenic Tissue in Youth Using Automated Insulin Delivery: A Paired Post Hoc Analysis.

Journal of diabetes science and technology·2026
Same author

Automated Insulin Delivery Systems in Hospitals: A Systematic Review with Meta-Analysis.

Diabetes technology & therapeutics·2026
Same author

Glycemic Responses to Two Different Exercise Modalities in Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems: The AIDing Exercise Study.

Diabetes technology & therapeutics·2026

Related Experiment Video

Updated: Jul 18, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

Glucose Monitoring Metrics in Individuals With Type 1 Diabetes Using Different Treatment Modalities: A Real-World

Kirsten Nørgaard1,2, Ajenthen G Ranjan1, Christian Laugesen1

  • 1Copenhagen University Hospital, Steno Diabetes Center Copenhagen, Herlev, Denmark.

Diabetes Care
|August 23, 2023
PubMed
Summary

Automated insulin delivery (AID) systems show superior glycemic control compared to other insulin methods for type 1 diabetes management. AID offers improved time in range and achievement of glycemic targets, making it a preferred choice.

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.6K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

68.7K

Related Experiment Videos

Last Updated: Jul 18, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.6K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

68.7K

Area of Science:

  • Endocrinology
  • Diabetes Technology
  • Metabolic Medicine

Background:

  • Continuous glucose monitoring (CGM) provides valuable real-world data on glycemic control.
  • Different insulin treatment modalities exist for type 1 diabetes, each with varying impacts on glucose management.

Purpose of the Study:

  • To investigate the association between CGM-derived glycemic metrics and various insulin treatment strategies.
  • To compare the effectiveness of multiple daily injections (MDI), sensor-augmented pumps (SAP), and automated insulin delivery (AID) in managing type 1 diabetes.

Main Methods:

  • A cross-sectional study analyzed real-world data from 3,184 individuals with type 1 diabetes using CGM.
  • Participants were categorized into MDI, insulin pump with unintegrated CGM (SUP), SAP, and AID groups.
  • Primary outcome was time in range (TIR); secondary outcomes included other glucose metrics and HbA1c.

Main Results:

  • Automated insulin delivery (AID) users achieved the highest median time in range (72.1%).
  • Significantly higher proportions of SAP and AID users met all glycemic targets compared to MDI users.
  • Odds ratios for achieving targets were 2.4 for SAP and 9.4 for AID versus MDI without alarms.

Conclusions:

  • Automated insulin delivery (AID) demonstrates superior glycemic control compared to other insulin treatment modalities when used with CGM.
  • AID should be considered the preferred insulin pump therapy option for individuals with type 1 diabetes.
  • While potential biases exist, the data strongly support AID's efficacy in improving diabetes management.